Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individualized peptide vaccine trial in pediatric and AYA patients with metastatic fusion-driven sarcomas after standard treatment
2022-002793-91Phase 2Active
- Sponsor
- University Hospital Tübingen
- Start
- Jan 2023
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of IPX-Vaccine in Bone and soft tissue sarcoma, Ewing sarcoma, rhabdomyosarcoma (RMS) and 1 more, sponsored by University Hospital Tübingen. Started Jan 2023; status: active.
02
Drugs
IPX-Vaccine
03
Conditions
Bone and soft tissue sarcomaEwing sarcomarhabdomyosarcoma (RMS)synovial sarcoma (SS)
Beyond the preview
Go deeper on 2022-002793-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002793-91.